Form 4: Stereotaxis Director Myriam Curet Receives Significant Equity Grant

Stereotaxis, Inc. Director Myriam Curet was granted 43,668 restricted share units of common stock, increasing her beneficial ownership to 345,110 shares.

Summary

• Myriam Curet, a Director of Stereotaxis, Inc. (STXS), acquired 43,668 shares of common stock on July 1, 2025.
• This acquisition was a grant of restricted share units (RSUs) with a price of $0 per unit, where each RSU represents a right to receive one share of common stock.
• Following this transaction, Myriam Curet beneficially owns a total of 345,110 shares of Stereotaxis, Inc. common stock.
• The restricted share units are set to vest on the earliest of three conditions: the fifth anniversary of the award date, the termination of the director's service on the board, or a Change of Control as defined in the award documents.

Sentiment

Score: 7

Explanation: The grant of restricted share units to a director is a positive step for aligning management and shareholder interests, indicating continued commitment and a standard practice in corporate governance.

Positives

• The grant of 43,668 restricted share units to Director Myriam Curet aligns her interests with those of shareholders, fostering a long-term perspective.
• Increased beneficial ownership to 345,110 shares demonstrates continued commitment and confidence from a key board member in the company's future.
• The inclusion of vesting conditions tied to service and a Change of Control provides incentives for sustained performance and strategic outcomes.

Negatives

• No specific negative information is contained within this Form 4 filing.

Risks

• No specific risks are detailed in this Form 4 filing, as it primarily reports an insider transaction.

Future Outlook

The restricted share units granted to Director Myriam Curet are set to vest on the earliest of the fifth anniversary of the award date, the termination of her service on the board, or a Change of Control, indicating a long-term incentive structure for her continued contribution.

Industry Context

The grant of restricted share units to a director is a common practice in publicly traded companies across various industries, serving as a form of non-cash compensation designed to align the interests of board members with those of shareholders. This particular transaction for Stereotaxis, Inc. reflects standard corporate governance practices for director remuneration.

Comparison to Industry Standards

• Director equity grants, such as the restricted share units received by Myriam Curet, are a standard component of compensation packages for board members in publicly traded companies.
• The mechanism of granting equity to align director incentives with shareholder value is consistent with global benchmarks for corporate governance, similar to practices seen in other medical device companies like Intuitive Surgical (ISRG) or Medtronic (MDT), though the specific number of units and total beneficial ownership are unique to Stereotaxis, Inc. and its compensation policies.

Corporate Governance

Related Party Transactions

• The grant of restricted share units to a director constitutes a related party transaction, which is a standard and disclosed form of compensation for board members.

Stakeholder Impact

• Shareholders: Interests are further aligned with the director through equity ownership, potentially leading to more shareholder-centric decision-making and long-term value creation.

Next Steps

• Vesting of the 43,668 restricted share units based on the specified conditions (fifth anniversary of award, termination of service, or Change of Control).

Key Dates

Keywords

Stereotaxis, STXS, Form 4, insider transaction, beneficial ownership, equity grant, restricted share units, director compensation, corporate governance